Fortis Healthcare Limited (FORTIS) announced signing definitive agreements with Seth Sunder Lal Jain Charitable Eye Hospital to provide healthcare services to a new 400+ bedded super specialty hospital in Ashok Vihar, New Delhi. The hospital is expected to commence operations in 3-4 years, subject to necessary approvals.

Strategic Collaboration

The agreements have been executed by FHL’s wholly-owned subsidiary, Fortis Hospotel Limited (FHTL). Under the Healthcare Services Agreement (HSA), FHTL has long-term exclusive rights to provide specified inpatient healthcare services and specialized equipment such as Cath Lab, LINAC, PET-CT, Surgical Robot, etc. in consideration of an agreed service fee to be paid by SLJ Society.

Hospital Development

The hospital will be owned, operated, and managed by SLJ Society, with Fortis providing the healthcare services pursuant to the agreement. The land, building, and the associated civil and certain medical infrastructure will be owned and developed by the SLJ Society itself. For the purposes of construction, upgradation, and operation of the Hospital, FHTL will also provide a loan to the Society in a phased manner over the next 3-4 years based on construction progress.

Future Expansion

With a planned capacity of 400+ beds, which will be operationalized in phases, the hospital will be strategically located in one of Delhi’s key populous districts with a dense catchment in surrounding areas as well. The hospital will offer comprehensive and high-quality tertiary and quaternary healthcare services across key specialties, such as Oncology, Neurosciences, Cardiac Sciences, Gastroenterology, Orthopaedics, Renal Sciences, multi-specialty robotic surgeries, and Transplants. It will also fulfill applicable regulatory and social obligations by providing free inpatient and outpatient treatment to eligible patients under the EWS (Economically Weaker Sections) category.

Dr. Ashutosh Raghuvanshi, MD & CEO of the Company, said, “the signing of the Healthcare Services Agreement with SLJ Society marks an important collaboration aimed at enhancing access to quality healthcare in North-West Delhi, an underserved micro-market characterized by a dense residential population. Under this arrangement, the hospital will be owned, operated, and managed by SLJ Society, with Fortis providing healthcare services pursuant to the agreement. Pursuant to this, Fortis’ services would extend to more than 3,400 beds across the Delhi – NCR region going forward. We remain focused on leveraging our clinical expertise and healthcare capabilities through strategic collaborations to support improved patient outcomes and access to high-quality care.”

Source: NSE Corporate Announcement

Fundamental & Technical Analysis of Fortis Healthcare Limited

Fortis Healthcare Limited belongs to the Healthcare › Medical Care Facilities sector. Here’s a quick read on where the business and the stock stand today.

Fortis falls 9.2% over three months and has not found a floor yet. The PEG reaches 3.02. The stock trades on brand and index weight, not on growth. Revenue grows at 13.3% and profits at 21.0% CAGR. The market consistently rewards this kind of compounding. The stock holds at 31% of its 52-week range with RSI at 33. In other words, neither side has a clear edge right now. Revenue grows at 13.3% and profits at 21.0% CAGR, with D/E of 0.00. Meanwhile, the stock dips 9.2% in three months without any fundamental deterioration. Consequently, the stock quietly becomes cheaper relative to earnings power. For long-term investors, that is a feature. Check Fundamentals of Fortis Healthcare Limited.

Fortis Healthcare Limited (FORTIS) breaks below support, falling 5% today. This decline follows the recent concall for Q1FY27, where the company reported a 17.5% increase in consolidated revenue but also highlighted a slight decrease in EBITDA margins and an increase in net debt. The stock’s move today appears to be a reaction to these mixed signals, coupled with the breakdown below the 6M support trendline. Fortis operates in the healthcare sector, specifically medical care facilities, and today’s move seems to be more company-specific rather than a sector-wide trend.

Technical setup — trendlines & DMA

From a technical standpoint, Fortis Healthcare is currently trading below its 6M support trendline, which ended at ₹937.88, indicating a breakdown. The stock is now 5.83% below this support level and 9.17% below the resistance trendline at ₹967.56. The 50-DMA stands at ₹958.6, and the 200-DMA is at ₹914.4, with the stock currently trading just above the 200-DMA but below the 50-DMA, suggesting a recovery mode. In terms of its 52W range, the stock is in the middle third, 35% up from the 52W low and 19.7% down from the 52W high, indicating that there is still room for both upward and downward movement.

Fundamentals & business context

On the fundamental front, Fortis Healthcare’s PE of 68.7, coupled with an 11.0% profit margin and a revenue CAGR of 13.3%, suggests that the stock is trading at a premium relative to its current earnings. The 21.0% profit CAGR over 5 years indicates strong growth, but the high PE ratio may reflect investor expectations of continued growth. With 47.9% institutional ownership, it appears that institutional investors have a significant stake in the company, which could indicate confidence in its long-term prospects. There was no specific NSE catalyst today, but the recent concall data provides context for the stock’s performance.

Algorithmic scorecard

The algorithmic scorecard for Fortis Healthcare reflects a balanced view, with strengths and weaknesses across both fundamental and technical metrics. One of the strongest signals is the consistent revenue growth every year, indicating exceptional business stability. Another strong point is the very low debt level, with a D/E ratio of 0.00, showcasing excellent financial health. On the weaker side, the stock is considered overvalued with a PEG of 3.27, suggesting it is expensive relative to its growth rate. Additionally, the negligible dividend yield of 0.11% offers little to no income for investors. These factors together paint a picture of a company with solid growth and financial health but at a premium valuation that may not align with its current earnings.

Company outlook

Fortis Healthcare’s recent concall for Q1FY27 revealed several strengths and weaknesses. On the positive side, the company reported a 17.5% increase in consolidated revenue and a 15.8% increase in consolidated operating EBITDA pre-ESOP expenses. The diagnostic business showed an improved operating EBITDA margin. However, the company also faced challenges such as a decrease in consolidated operating EBITDA margin and an increase in net debt. Hospital occupancy remained steady, and margin expansion in certain facilities is expected to take time. These mixed results provide a nuanced view of the company’s current performance.

Looking ahead, Fortis Healthcare’s management has outlined several key initiatives and targets. They are maintaining guidance for a 25% EBITDA margin after running the ESOP cost and expect an improvement in EBITDA margin by 100 basis points at the consolidated level for FY ’27. Revenue growth is expected to be around 12%-13%, with an EBITDA margin in the range of 24%-25% for the diagnostic business. The company is focusing on improving occupancy and EBITDA margins in key facilities such as Manesar and Greater Noida, with an expectation of reaching mid-teens EBITDA margins by the year-end. Additionally, plans to operationalize another 400 beds in the remaining 3 quarters of the year, with a major contribution from the flagship hospital, FMRI, are on track.

Get all details on FORTIS — P&L, peers, shareholding and more on TradeAlone.

Fortis Healthcare Limited (FORTIS) neared resistance today, gaining +5% to ₹967.35 on the NSE, driven by the release of its Q1 FY27 results which showed a 17.5% year-on-year increase in revenue and an Operating EBITDA margin of 22.3%. This move is company-specific, as the stock tests resistance at ₹968, just 0.0% away, after bouncing from support at ₹938. The healthcare sector, particularly medical care facilities, has seen mixed performance, making Fortis’s move noteworthy.

Technical setup — trendlines & DMA

From a technical perspective, Fortis Healthcare is currently testing the 6-month resistance trendline at ₹968, with today’s price just 0.02% below this level. The stock has rebounded from the 6-month support trendline at ₹937.95, which is 3.04% below the current price. The 50-day moving average (DMA) at ₹960.0 is above the 200-DMA at ₹917.1, indicating a bullish trend, though the stock is currently in recovery mode as it trades above the 200-DMA but below the 50-DMA. In the 52-week range of ₹766.8 to ₹1104.3, the current price is in the middle third, suggesting that a significant portion of the potential move may already be priced in.

Fundamentals & business context

Fundamentally, Fortis Healthcare’s PE of 66.8, coupled with profit margins of 11.4% and a revenue CAGR of 13.3%, suggests that the market may be pricing in future growth rather than current earnings. The company’s 47.9% institutional ownership indicates a level of confidence from sophisticated investors, though the absence of a specific NSE catalyst today means the move is likely driven by the strong Q1 results and the approaching resistance level.

Algorithmic scorecard

The overall algorithmic scorecard for Fortis Healthcare reflects a balanced view, with a strong fundamental score and a weaker technical score. The strongest signals include the company’s excellent revenue CAGR of 21.0% and very low debt levels with a D/E ratio of 0.27, indicating robust growth and financial health. On the weaker side, the stock’s overvalued status with a PEG of 3.18 and negligible dividend yield of 0.11% pose risks. These factors suggest that while the company is growing strongly, its valuation may be stretched, and income-seeking investors may find limited appeal.

Company outlook

Fortis Healthcare’s management has outlined an optimistic outlook for the current financial year, expecting 15% plus revenue growth and an additional 150 basis point margin improvement for the hospital business. The diagnostics business is projected to maintain EBITDA margins around 23% to 24%. The company plans to add 1,800 beds over the next four years through brownfield expansion, with an initial target of opening around 100 beds in a new tower at FMRI. Capex is expected to be around INR 900 crores annually, with a focus on both maintenance and growth capex. These initiatives aim to drive double-digit revenue growth, with 70% coming from volume and 30% from value.

Get all details on FORTIS — P&L, peers, shareholding and more on TradeAlone.